4//SEC Filing
LAPORTE KATHLEEN 4
Accession 0001193125-25-321152
CIK 0001641281other
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 5:13 PM ET
Size
33.0 KB
Accession
0001193125-25-321152
Insider Transaction Report
Form 4
LAPORTE KATHLEEN
Director
Transactions
- Award
Director Stock Option (Right to Buy)
2025-12-12+1,392→ 1,392 totalExercise: $5.44Exp: 2030-12-28→ Common Stock (1,392 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,392→ 0 totalExercise: $88.20Exp: 2030-12-28→ Common Stock (1,392 underlying) - Award
Director Stock Option (Right to Buy)
2025-12-12+1,250→ 1,250 totalExercise: $5.44Exp: 2032-03-23→ Common Stock (1,250 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,250→ 0 totalExercise: $60.60Exp: 2032-03-23→ Common Stock (1,250 underlying) - Award
Director Stock Option (Right to Buy)
2025-12-12+1,100→ 1,100 totalExercise: $5.44Exp: 2034-06-11→ Common Stock (1,100 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,100→ 0 totalExercise: $15.36Exp: 2034-06-11→ Common Stock (1,100 underlying)
Footnotes (9)
- [F1]The option is fully vested and exercisable.
- [F2]The reporting person agreed to cancellation of an option granted on December 29, 2020, in exchange for a new option having a lower exercise price.
- [F3]The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price.
- [F4]The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price.
- [F5]The reporting person agreed to cancellation of an option granted on December 14, 2022, in exchange for a new option having a lower exercise price.
- [F6]The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price.
- [F7]The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price.
- [F8]The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
- [F9]The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.
Documents
Issuer
Bolt Biotherapeutics, Inc.
CIK 0001641281
Entity typeother
Related Parties
1- filerCIK 0001196201
Filing Metadata
- Form type
- 4
- Filed
- Dec 15, 7:00 PM ET
- Accepted
- Dec 16, 5:13 PM ET
- Size
- 33.0 KB